Mustang Bio, Inc. (MBIO) News

Mustang Bio, Inc. (MBIO): $0.27

0.01 (-4.61%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

C

Add MBIO to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#115 of 339

in industry

Filter MBIO News Items

MBIO News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

MBIO News Highlights

  • MBIO's 30 day story count now stands at 2.
  • Over the past 27 days, the trend for MBIO's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • BIO, CRS and GENE are the most mentioned tickers in articles about MBIO.

Latest MBIO News From Around the Web

Below are the latest news stories about MUSTANG BIO INC that investors may wish to consider to help them evaluate MBIO as an investment opportunity.

Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual Meeting

Data showed favorable safety profile, complete response rate and durability in the treatment of patients with relapsed or refractory indolent B-cell Non-Hodgkin Lymphoma 100% of patients with follicular lymphoma achieved a complete response; no occurrence of CRS above grade 1 and no ICANS of any grade Complete responses observed in patients previously treated with CD19-targeted CAR T-cell therapy Outpatient administration found to be feasible WORCESTER, Mass., Dec. 11, 2023 (GLOBE NEWSWIRE) -- M

Yahoo | December 11, 2023

Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

WORCESTER, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced financial results and recent corporate highlights for the third quarter that ended September 30, 2023. Manuel Litchman, M.D., President and Chief Executive Officer of Mustang, said, “I

Yahoo | November 14, 2023

Mustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual Meeting

Updated interim data from Mustang’s multicenter Phase 1/2 clinical trial demonstrate favorable safety and efficacy profile of MB-106 in heavily pre-treated lymphoma patientsWORCESTER, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced that interi

Yahoo | November 2, 2023

Mustang Bio Announces Closing of $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

WORCESTER, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules, for the purchase and sale of 2,588,236 of its shares of com

Yahoo | October 30, 2023

Mustang Bio Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

WORCESTER, Mass., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 2,588,236 of its shares of common stock (or common stock equivalents in li

Yahoo | October 26, 2023

Mustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma

MB‐101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus) are separately well tolerated in patients with recurrent GBM in ongoing Phase 1 clinical trials; preclinical data support potential of MB-109 to optimize clinical results The Phase 1 study will assess the safety, tolerability and efficacy of MB-109 in patients with recurrent glioblastoma and high-grade astrocytoma and is expected to begin enrolling patients in 2024 WORCHESTER, Mass., Oct. 26, 2023 (GLOBE NEWSWIRE) --

Yahoo | October 26, 2023

Mustang Bio to Participate in Upcoming September 2023 Investor Conferences

WORCESTER, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced that Manuel Litchman, M.D., President and Chief Executive Officer, will participate in two upcoming investor conferences in New York City. Details of the events are as follows: H.C. W

Yahoo | September 7, 2023

Mustang Bio Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy

Initial data show clinical responses from four of four indolent lymphoma patients, including complete response in follicular lymphoma patient previously treated with CD19 CAR-T cell therapy Aligns with ongoing results from investigator-sponsored trial at Fred Hutch that show ongoing complete remission for more than three years Update on data presented at 5th iwCAR-T, Scottsdale, AZ Safety Review Committee unanimously approved dose escalation of the indolent lymphoma arm WORCESTER, Mass., Aug. 16

Yahoo | August 16, 2023

Mustang Bio Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

WORCESTER, Mass., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced financial results and recent corporate highlights for the second quarter ended June 30, 2023. Manuel Litchman, M.D., President and Chief Executive Officer of Mustang, said, “In the sec

Yahoo | August 14, 2023

Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

Total net revenue was $17.4 million in the second quarter of 2023, a 40% increase from $12.4 million in the first quarter of 2023 Positive topline results from two Phase 3 clinical trials evaluating DFD-29 demonstrated achievement of co-primary and all secondary endpoints versus placebo and Oracea® (doxycycline) with no significant safety issues Fortress is advancing several late-stage clinical assets with two NDA submissions anticipated in the second half of 2023 for DFD-29 and CUTX-101 Cosibel

Yahoo | August 14, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!